Stock Track | AngioDynamics Plummets 17.23% Intraday Amid Net Loss, CEO Retirement, and Tariff Impact

Stock Track
01/06

AngioDynamics (ANGO) saw its shares plummet by 17.23% during Tuesday's intraday trading session. The sharp decline followed the company's mixed second-quarter financial results and significant corporate updates.

The medical technology company reported a net loss of $6.4 million for the quarter, despite beating sales estimates with $79.4 million in revenue. While adjusted EPS of $0.00 surpassed expectations of a $0.09 loss, investors reacted negatively to the overall net loss and ongoing challenges.

Adding to the uncertainty, AngioDynamics announced that CEO Jim Clemmer will retire in fiscal 2027, with the board initiating a search for his successor. The company also maintained its forecast of a $4.0-$6.0 million negative impact from tariffs for fiscal 2026, offsetting some optimism from its raised full-year sales and EBITDA guidance.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10